Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19683175 | 1.00 | ITGB3 (0.58) | ITGB3ITGA2BPTPN1GRIA1FAAH | |
| SCHEMBL23974228 | 0.89 | ITGB3 (0.53) | ITGB3ITGA2BPTPN1GRIA1FAAH | |
| SCHEMBL24276096 | 0.86 | ITGB3 (0.59) | ITGB3ITGA2BPTPN1ALDH1A1HDAC1 | |
| SCHEMBL23974227 | 0.86 | ITGB3 (0.59) | ITGB3ITGA2BPTPN1ALDH1A1HDAC1 | |
| SCHEMBL19683215 | 0.84 | ITGB3 (0.49) | ITGB3ITGA2BPTPN1GRIA1FAAH | |
| SCHEMBL19683213 | 0.83 | ITGB3 (0.48) | ITGB3ITGA2BPTPN1GRIA1FAAH | |
| SCHEMBL24276204 | 0.83 | ITGB3 (0.56) | ITGB3ITGA2BPTPN1GRIA1FAAH | |
| SCHEMBL19682976 | 0.82 | ITGB3 (0.47) | ITGB3ITGA2BPTPN1PSMB5 | |
| SCHEMBL13963521 | 0.81 | ITGB3 (0.68) | ITGB3ITGA2BFAAHALDH1A1HDAC1 | |
| SCHEMBL9666396 | 0.80 | FAAH (0.65) | ITGB3ITGA2BPTPN1FAAHHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464336-B1 | COMPOUNDS | ATHIRA PHARMA INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210340176-A1 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340176-A1 | Compounds | BACE1, BDNF, CLN6 | ITGB3 4559/4885ITGA2B 4787/4885PTPN1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.